Brief Today
2016 07.18
Fangyuan Pharmaceutical Invests Heavily in R&D of New Drugs for Treatment of Superbacteria

CHANGZHOU, ChinaJuly 12, 2016 /PR Newswire/ -- The Chinese Academy of Engineering Wang Guangji Academic Workstation has been set up on the premises of Changzhou Fangyuan Pharmaceutical Co., Ltd. in Changzhou National Hi-Tech District. The workstation will sign a strategic cooperation agreement with Fangyuan Pharmaceutical and the China State Institute of Pharmaceutical Industry (CSIPI), for the further development of aminoglycosides, antibacterial therapeutic agents that can reduce the side effects of antibiotics on the human body.

The result of nearly 10 years of effort, Fangyuan Pharmaceutical's international R&D team has finally developed the preparation process for arbekacin sulfate, and will file an application for clinical research. The drug is expected to be put into production in 2018. Arbekacin sulfate, a generic drug that is difficult to produce, is used to treat superbacteria, and has shown significant effectiveness since its launch in 1990.

Fangyuan Pharmaceutical has set up an institute (the Jiangsu Institute of Microbiology), two R&D workstations (the Nanjing University Chen Hongyuan Academic Workstation and the China Pharmaceutical University Wang Guangji Academic Workstation) and three R&D centers (the Jiangsu Semi-Synthetic Antibiotics Engineering Research Center, the Jiangsu Microbial Pharmaceutics Engineering Research Center and the Jiangsu Enterprise Technology Center), and brought in foreign specialists who will work with the firm and the various R&D units to jointly develop innovative drugs in one of the world's most advanced scientific fields.

The etimicin sulfate HPLC-PAD test method jointly developed by Fangyuan Pharmaceutical and partnering organizations was announced in Chinese Pharmacopoeia 2015 and copied by pharmacopoeias in Europe and the United States. The company is developing two Class 1 (according to the Chinese FDA classification system) new drugs for the treatment of leukemia and colon cancer, as well as four Class 3 generic drugs.

Changzhou National Hi-Tech District's Life and Health Industrial Park is home to Changzhou Qianhong Biopharma, Zilong Pharmaceutical, Genovate Biotechnology, Intersurgical, Changzhou Cross-straits Life Science Industrial Park, and Chinese Academy of Sciences Genetic Resources (Southern China) R&D Center, with an aggregate investment exceeding20 billion yuan (approx. US$3 billion). The park has evolved into an environmentally-friendly industrial zone that mainly produces pharmaceutical preparations and medical devices.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fangyuan-pharmaceutical-invests-heavily-in-rd-of-new-drugs-for-treatment-of-superbacteria-300297088.html

SOURCE The Public Promotion Department of Changzhou Xinbei District Commission of CCP